Pharmacological Insights into Levodopa-induced Motor Fluctuations in Patients with Parkinson's Disease.
作者信息
Rascol Olivier
机构信息
Clinical Investigation Center INSERM 1436 Department of Clinical Pharmacology and Neurosciences University Hospital of Toulouse UMR Tonic 1214, University of Toulouse III Toulouse France.
NS-Park/French Clinical Research Infrastructure Network (F-CRIN) and Toulouse Neuro-Degenerative Center (NeuroToul) Network of Centers of Excellence in Neurodegeneration (COEN) Toulouse France.
出版信息
Mov Disord Clin Pract. 2016 Sep 4;3(6):523-526. doi: 10.1002/mdc3.12389. eCollection 2016 Nov-Dec.
Abstract
摘要
相似文献
1
Pharmacological Insights into Levodopa-induced Motor Fluctuations in Patients with Parkinson's Disease.帕金森病患者左旋多巴诱发运动波动的药理学见解
Mov Disord Clin Pract. 2016 Sep 4;3(6):523-526. doi: 10.1002/mdc3.12389. eCollection 2016 Nov-Dec.
2
Motor fluctuations due to interaction between dietary protein and levodopa in Parkinson's disease.帕金森病中饮食蛋白质与左旋多巴相互作用导致的运动波动
J Clin Mov Disord. 2016 May 26;3:8. doi: 10.1186/s40734-016-0036-9. eCollection 2016.
3
The modern pre-levodopa era of Parkinson's disease: insights into motor complications from sub-Saharan Africa.帕金森病左旋多巴治疗前的现代时期：来自撒哈拉以南非洲地区对运动并发症的见解。
Brain. 2014 Oct;137(Pt 10):2731-42. doi: 10.1093/brain/awu195. Epub 2014 Jul 17.
4
The XINDI Study: A Randomized Phase III Clinical Trial Evaluating the Efficacy and Safety of Safinamide as Add-On Therapy to Levodopa in Chinese Patients with Parkinson's Disease with Motor Fluctuations.XINDI 研究：一项随机、III 期临床试验，评估了沙芬酰胺作为左旋多巴添加治疗对中国有运动波动的帕金森病患者的疗效和安全性。
CNS Drugs. 2022 Nov;36(11):1217-1227. doi: 10.1007/s40263-022-00958-6. Epub 2022 Nov 8.
5
Rhythm-specific modulation of the sensorimotor network in drug-naive patients with Parkinson's disease by levodopa.左旋多巴对未经药物治疗的帕金森病患者感觉运动网络的节律特异性调节。
Brain. 2013 Mar;136(Pt 3):710-25. doi: 10.1093/brain/awt007. Epub 2013 Feb 18.
6
Parkinson's Disease and development of levodopa induced motor complications: Influence of baseline features and first medical approach.帕金森病与左旋多巴诱发的运动并发症的发生：基线特征和首次治疗方法的影响
Porto Biomed J. 2016 Sep-Oct;1(4):136-141. doi: 10.1016/j.pbj.2016.08.001. Epub 2016 Sep 17.
7
Tozadenant (SYN115) in patients with Parkinson's disease who have motor fluctuations on levodopa: a phase 2b, double-blind, randomised trial.托扎丹特（SYN115）治疗伴有左旋多巴运动波动的帕金森病患者的疗效：一项 2b 期、双盲、随机试验。
Lancet Neurol. 2014 Aug;13(8):767-76. doi: 10.1016/S1474-4422(14)70148-6. Epub 2014 Jul 6.
8
Rasagiline as Adjunct to Levodopa for Treatment of Parkinson's Disease: A Systematic Review and Meta-Analysis.雷沙吉兰作为左旋多巴的辅助药物治疗帕金森病：一项系统评价和荟萃分析。
Parkinsons Dis. 2022 Aug 30;2022:4216452. doi: 10.1155/2022/4216452. eCollection 2022.
9
Natural history of motor symptoms in Parkinson's disease and the long-duration response to levodopa.帕金森病运动症状的自然史和左旋多巴的长期反应。
Brain. 2020 Aug 1;143(8):2490-2501. doi: 10.1093/brain/awaa181.
10
Dyskinesias and motor fluctuations in Parkinson's disease. A community-based study.帕金森病中的异动症和运动波动。一项基于社区的研究。
Brain. 2000 Nov;123 ( Pt 11):2297-305. doi: 10.1093/brain/123.11.2297.
本文引用的文献
1
Apomorphine Therapy: The Hazard of Left Over Needles.阿扑吗啡疗法：残留针头的危害。
Mov Disord Clin Pract. 2015 Mar 16;2(2):199-200. doi: 10.1002/mdc3.12143. eCollection 2015 Jun.
2
Enteral Levodopa Therapy in Advanced Parkinson's Disease with Gastroparesis.晚期帕金森病合并胃轻瘫的肠内左旋多巴治疗
Mov Disord Clin Pract. 2015 Jun 4;2(3):321-322. doi: 10.1002/mdc3.12189. eCollection 2015 Sep.
3
Adenosine 2A Receptor Antagonists for the Treatment of Motor Symptoms in Parkinson's Disease.用于治疗帕金森病运动症状的腺苷2A受体拮抗剂
Mov Disord Clin Pract. 2015 Jul 25;2(4):331-340. doi: 10.1002/mdc3.12187. eCollection 2015 Dec.
4
Apomorphine Subcutaneous Injection for the Management of Morning Akinesia in Parkinson's Disease.阿扑吗啡皮下注射治疗帕金森病晨僵
Mov Disord Clin Pract. 2017 Jan-Feb;4(1):78-83. doi: 10.1002/mdc3.12350. Epub 2016 May 25.
5
Apomorphine: A potential modifier of amyloid deposition in Parkinson's disease?阿扑吗啡：帕金森病中淀粉样蛋白沉积的潜在调节剂？
Mov Disord. 2016 May;31(5):668-75. doi: 10.1002/mds.26422. Epub 2015 Oct 13.
6
Oral r-(-)-11-o-valeryl-n-n-propylnoraporphine reverses motor deficits in mptp-treated marmosets.口服 r-(-)-11-正戊酰基-n-正丙基去甲阿朴啡可逆转mptp 处理的狨猴的运动缺陷。
Mov Disord. 2016 Sep;31(9):1381-8. doi: 10.1002/mds.26626. Epub 2016 May 2.
7
New treatments for levodopa-induced motor complications.左旋多巴诱导运动并发症的新治疗方法。
Mov Disord. 2015 Sep 15;30(11):1451-60. doi: 10.1002/mds.26362. Epub 2015 Aug 21.
8
Zonisamide improves wearing-off in Parkinson's disease: A randomized, double-blind study.唑尼沙胺改善帕金森病的“开-关”现象：一项随机、双盲研究。
Mov Disord. 2015 Sep;30(10):1343-50. doi: 10.1002/mds.26286. Epub 2015 Jun 12.
9
Apomorphine hydrochloride for the treatment of Parkinson's disease.盐酸阿扑吗啡用于治疗帕金森病。
Expert Rev Neurother. 2015;15(7):723-32. doi: 10.1586/14737175.2015.1051468. Epub 2015 Jun 2.
10
Gastroretentive carbidopa/levodopa, DM-1992, for the treatment of advanced Parkinson's disease.胃滞留型卡比多巴/左旋多巴（DM-1992）治疗晚期帕金森病。
Mov Disord. 2015 Aug;30(9):1222-8. doi: 10.1002/mds.26219. Epub 2015 Apr 2.
Zotero 插件